Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies - Episode 13
Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens
A panelist discusses how the postinfusion challenges with afamitresgene autoleucel (afami-cel), such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, are generally manageable and time limited compared with the chronic cumulative toxicities seen with conventional chemotherapy regimens, though careful monitoring and prompt intervention remain essential.
Video content above is prompted by the following:
- What are some of the challenges you are seeing in patients post infusion, and how does that compare with your prior experience using standard-of-care regimens?
Related Content:
